Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma

BACKGROUND: Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR‐TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome drug resistance. METHODS: We used P...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Park, Hee Sun, Lee, Da‐Hye, Kang, Da Hyun, Yeo, Min‐Kyung, Bae, Goeun, Lee, Dahye, Yoo, Geon, Kim, Ju‐Ock, Moon, Eunyoung, Huh, Yang Hoon, Lee, Sang‐Hee, Jo, Eun‐Kyeong, Cho, Sang Yeon, Lee, Jeong Eun, Chung, Chaeuk
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Cancer Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7926029/
https://ncbi.nlm.nih.gov/pubmed/33486901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3734
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars